$ cat ./records/gates-foundation-and-cepi-back-aspen-pharmacare-for-african-vacci-2022.txt
Gates Foundation and CEPI Back Aspen Pharmacare for African Vaccine Manufacturing
[RECORD.TXT] · cat --full
The Gates Foundation and CEPI each committed $15 million to Aspen Pharmacare, Africa's largest pharmaceutical company, to establish domestic manufacturing of routine childhood vaccines — pneumococcal, rotavirus, hexavalent, and meningococcal — on the continent. The deal included technology transfer from Serum Institute of India starting in early 2023. The initiative was a direct response to COVID-19 exposing Africa's near-total dependence on imported vaccines during a global supply crisis.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Upside Foods Achieves Unicorn Status in $400 Million Round Backed by Gates
Next →
Gates Foundation Commits $1.2 Billion to Global Polio Eradication Initiative
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.